FB-TW

Showing posts with label polypill. Show all posts
Showing posts with label polypill. Show all posts

Friday, July 20, 2012

The Polypill has never been proven to benefit anyone - Briffa

It’s easy to fall for the polypill hype, but the reality is this medication has never been proven to benefit anyone

There’s been a ton of press over the last couple of days regarding a study of what is termed the ‘polypill’ – a combination medication conceived more than a decade ago with, supposedly, the prevention of heart disease and stroke in mind. The original ‘formulation’ combined blood pressure- and cholesterol-lowering medications, along with aspirin and vitamin B12. From time to time in the scientific literature we have seen studies which purport to support the idea of polypill taking for disease prevention. And the latest of these was published this week. Here, in short, is the study design and what it showed. After that, I’ll offer my own interpretation of the data.

This latest study tested the impact of a polypill comprising the following drugs:
  • amlodipine (blood pressure lowering medication) – 2.5 mg
  • losartan (blood pressure lowering medication) – 25 mg
  • hydrochlorothiazide (blood pressure lowering medication) – 12.5 mg
  • simvastatin (a statin) – 40 mg
The medication was given for 12 weeks to men and women aged 50 and over. At another time, they took a placebo for 12 weeks. In this sense, individuals acted as their own ‘controls’ in this study.

Individuals were selected for the study on the basis of two criteria:
  1. They needed to be currently taking at least one of the medications in the polypill
  2. They needed to be aged 50 or over
The impact on blood pressure and cholesterol levels was assessed. The polypill did bring significant reductions here. The authors estimate from the degree of reductions here that heart disease and stroke would be reduced by 72 and 64 per cent respectively. Impressive numbers. There’s talk of this extending life by a decade or more.

But here’s the thing: this study simply can’t be used to judge whether the polypill prevent cardiovascular disease and delays death. These ideas are based on speculation based on the idea that lowering blood pressure and cholesterol translates into significant benefits for health. Yet, as I explored most recently here and here, blood pressure and statin medications are generally very ineffective for the purposes of disease prevention and preventing death. Most people who take these drugs just won’t benefit.

This is particularly the case when individuals are deemed to be at low risk of cardiovascular disease. Normally, medication is prescribed on the basis of, say, blood pressure or cholesterol levels. But not in this study: here people were selected on the basis of age, irrespective of perceived risk. Of course it’s possible that some might benefit from the polypill, but it’s also likely that many more will not.

And of course the drugs in the polypill are not without risk. Any one of these medications on its own might cause problems, but the risk is magnified when medication are taken in combination. The design of the study (individuals had to be on at least one of the drugs in the polypill prior to the study) essentially preselects for individuals who, compared to members of the general population, are more likely to tolerate the medication being tested. So, risk of side-effects in the study population would be generally lower than we would expect to see in real life.

But, all of this is a diversion from the main point that we simply cannot predict the value of a drug on its impact on so-called ‘surrogate markers’ such as blood pressure and cholesterol. I mean, who would have predicted that ezetimibe, a potent cholesterol-lowerer, would never be shown to have benefits for health, or that the drug torcetrapib (which lowers ‘bad’ cholesterol and raises ‘good’ cholesterol) happens to increase the risk of people dying?

If we want to know how effective the polypill is, we need to test its impact on health. What impact does the polypill have on risk of heart disease, stroke and overall risk of death? We just don’t know because this latest study does not tell us. There are four previous polypill studies in the literature, and none of them look at these critically important ‘end points’ or ‘outcomes’ either.

The lead author of the latest study is David Wald, son of Professor Sir Nicholas Wald, co-inventor of the polypill. Professor Wald and a colleague (Professor Malcom Law) hold a polypill patent. I suspect they have at least some desire to cash in on their invention. But if they want to do that, why not test the polypill in a way which does not lead to wild speculation but cool hard facts? Perhaps if the polypill was properly studied we’d get to see that, like so many drugs, the ‘expected’ benefits fail to materialise. Maybe it’s better to keep the dream alive with a string of studies and articles that allow rampant speculation and uber-enthusiasm but simply fail to tell us what we really need to know.

References:
1. Wald DS, et al (2012) Randomized Polypill Crossover Trial in People Aged 50 and Over. PLoS ONE 7(7): e41297. doi:10.1371/journal.pone.0041297
==============================================================================================
Please read the complete article here.
====================
Sept 8, 2014 -  An FDA advisory committee looks at a new cardiovascular polypill about which FDA staff expressed serious reservations
===============================================================================================

Friday, January 28, 2011

The Polypill

From Prevention                    When will all this nonsense end?

================================================

WHO trial shows acceptability of polypill in a developing county


January 28, 2011
Lisa Nainggolan


Winston-Salem, NC - A pilot trial of a polypill for primary prevention of cardiovascular disease in Sri Lanka has shown this approach to be practical in a developing country and demonstrated that the polypill is highly acceptable among both patients and doctors [1].


"This study has fulfilled its purpose; we wanted to check the feasibility of doing a large-scale clinical trial with a polypill in a developing country, and from this perspective we now know that it's feasible," lead author Dr Elsayed Z Soliman (Wake Forest University School of Medicine, Winston-Salem, NC) told heartwire. Soliman and colleagues report their findings, the only such study sponsored by the World Health Organization (WHO), online January 5, 2011 in Trials.


The polypill was as effective as standard treatment in the population studied, but Soliman points out that "standard" treatment in this trial was administered from a tertiary-care center, and so it was "very sophisticated, complicated therapy."


And he says that although feasibility has been demonstrated, there are many questions to resolve before going forward with future, large trials of polypills. First, which patient population should a polypill be aimed at: primary or secondary prevention? What components and what doses should be in the pill? He notes that there is now a question mark over aspirin, at least in the primary-prevention population. And what should it be compared with? The separate components of the pill, placebo, or "standard treatment," and if the latter, how should that be defined? "All of these questions will never be answered by a single trial," he notes.


Polypill deemed acceptable by 90% of patients and >80% of doctors


Soliman et al conducted an open-label, parallel-group, randomized clinical trial that enrolled a total of 216 patients without established cardiovascular disease with an estimated 10-year total CVD risk score >20% from three sites in Sri Lanka. Patients were randomized to a polypill containing 75 mg of aspirin, 20 mg of simvastatin, 10 mg of lisinopril, and 12.5 mg of hydrochlorothiazide (Red Heart pill 2b; Reddy's Laboratories, India) or to standard practice and followed for three months.


Prespecified primary outcomes included reduction in systolic BP, total cholesterol, and estimated 10-year CVD risk. The researchers also assessed the recruitment process and the acceptability of the polypill by physicians and patients.


Of the patients, 203 completed the three-month treatment and returned for their three-month follow-up visit; both the polypill and standard treatment resulted in marked reductions in systolic BP, cholesterol, and 10-year risk of CVD, but there was no significant difference between the groups.
Of the patients who completed the trial, 90% said they would take the polypill "for life" if it were proven to be effective in reducing CVD risk; 86% of doctors supported the use of the polypill for primary prevention and 93% for secondary prevention.
Lessons learned should guide future studies
Soliman and colleagues explain they were unable to estimate the risk-factor reductions on the polypill "because the control group received similar treatment with individual drugs." However, they note that the polypill was "simpler" and achieved comparable risk-factor reductions, "highlighting its potential usefulness in the prevention of CVD."
And they point out that the three tertiary-care hospitals involved in this study "do not reflect the level of medical care provided at primary-care centers and secondary-level hospitals in Sri Lanka. Thus, the findings from the selected trial sites cannot be generalized to other levels of care.
"Further studies assessing the polypill in developing countries should take into consideration the study design lessons and challenges that we encountered," they conclude.
Other polypill trials are ongoing, including the TIPS 2 study and a collaborative effort called Single Pill to Avert Cardiovascular Events (SPACE), which includes the Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE), the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) and Improving Adherence Using Combination Therapy (IMPACT) trials.
==================================================================
UPDATE: Sept 8, 2014 -  An FDA advisory committee looks at a new cardiovascular polypill about which FDA staff expressed serious reservations
=======================================